|
| 强骨饮经KDM6A/EZH2调控BMSCs成脂分化 |
| Qianggu Yin regulates adipogenic differentiation of BMSCs via KDM6A/EZH2 |
| |
| DOI:10.3969/j.issn.1006-7108.2026.11.004 |
| 中文关键词: 骨质疏松症 强骨饮 成脂分化 赖氨酸特异性去甲基化酶 6A Zeste同源物增强子2 |
| 英文关键词:osteoporosis Qianggu Yin adipogenic differentiation lysine-specific demethylase 6A enhancer of zeste homolog 2 |
| 基金项目:浙江省自然科学基金重点项目(LZ22H270002) |
|
| 摘要点击次数: 66 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 从骨髓间充质干细胞(BMSCs)成骨/成脂分化平衡及赖氨酸特异性去甲基化酶 6A(KDM6A)/ Zeste同源物增强子2(EZH2)介导的Wnt蛋白家族7B? (Wnt7b)表观遗传调控角度,探讨强骨饮(Qianggu Yin, QGY)治疗骨质疏松症的作用机制。方法 采用双侧卵巢切除术建立雌性小鼠绝经后骨质疏松模型,随机分为假手术组、模型组、QGY组、EZH2抑制剂EPZ-6438组及QGY+EPZ-6438联合组,干预7周。通过Micro-CT检测股骨骨密度(BMD)及骨微结构(BV/TV、Tb.N、Tb.Th、Tb.Sp);HE染色观察骨组织形态;免疫组化检测股骨Wnt7b、β-连环蛋白(β-catenin)、KDM6A及EZH2蛋白表达。体外培养BMSCs,运用茜素红和油红O染色检测成骨与成脂分化;免疫荧光观察β-catenin核转位;qRT-PCR及Western blot检测Wnt通路相关基因/蛋白表达;ChIP-qPCR检测Wnt7b启动子区组蛋白H3第27位赖氨酸三甲基化(H3K27me3)水平;siRNA敲低KDM6A及药物干预验证机制。结果 OVX组骨微结构破坏、骨密度下降、骨髓脂肪增多,成骨细胞Wnt7b、β-catenin、KDM6A表达降低,EZH2表达升高(P<0.05)。QGY及EPZ-6438均显著改善上述变化,联合用药效果更优(P<0.05)。体外实验显示,QGY能促进BMSCs成骨分化并抑制成脂分化,并上调KDM6A表达抑制EZH2表达,同时降低Wnt7b启动子H3K27me3水平,激活Wnt7b/β-catenin通路。结论 QGY通过调控KDM6A/EZH2介导的H3K27me3甲基化水平,降低Wnt7b启动子区修饰,促进Wnt7b转录及蛋白表达,从而调控BMSCs成骨/成脂分化平衡,发挥治疗骨质疏松的作用。 |
| 英文摘要: |
| Objective To investigate the mechanism of Qianggu Yin (QGY) in the treatment of osteoporosis from the perspectives of the balance between osteogenic and adipogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and the epigenetic regulation of Wnt family member 7B (Wnt7b) mediated by lysine-specific demethylase 6A (KDM6A)/enhancer of zeste homolog 2 (EZH2). Methods A postmenopausal osteoporosis mouse model was established by bilateral ovariectomy (OVX) in female mice, and the mice were randomly divided into the sham group, model group, QGY group, EZH2 inhibitor EPZ-6438 group and QGY + EPZ-6438 combination group, with intervention for 7 weeks. Bone mineral density (BMD) and bone microarchitecture (BV/TV, Tb.N, Tb.Th, Tb.Sp) of the femur were detected by Micro-CT; bone histomorphology was observed by HE staining; and the protein expression of Wnt7b, β-catenin, KDM6A and EZH2 in the femur was detected by immunohistochemistry. BMSCs were cultured in vitro, and osteogenic and adipogenic differentiation were assessed by Alizarin Red and Oil Red O staining; nuclear translocation of β-catenin was observed by immunofluorescence; the expression of Wnt pathway-related genes and proteins was detected by qRT-PCR and Western blot; the level of trimethylation of histone H3 lysine 27 (H3K27me3) in the Wnt7b promoter region was detected by ChIP-qPCR; and the mechanism was verified by siRNA-mediated knockdown of KDM6A combined with pharmacological intervention. Results In the OVX group, bone microarchitecture was destroyed, BMD was decreased and bone marrow adiposity was increased; the expression of Wnt7b, β-catenin and KDM6A in osteoblasts was decreased, while the expression of EZH2 was increased (P<0.05). Both QGY and EPZ-6438 significantly ameliorated the above changes, and the combination treatment showed superior effects (P<0.05). In vitro experiments showed that QGY promoted osteogenic differentiation and inhibited adipogenic differentiation of BMSCs, up-regulated the expression of KDM6A while suppressing the expression of EZH2, decreased the level of H3K27me3 in the Wnt7b promoter, and activated the Wnt7b/β-catenin pathway. Conclusion QGY regulates the level of H3K27me3 methylation mediated by KDM6A/EZH2, reduces the modification in the Wnt7b promoter region, thereby promoting Wnt7b transcription and protein expression, and consequently regulates the balance between osteogenic and adipogenic differentiation of BMSCs, thus exerting a therapeutic effect on osteoporosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|